As CD4+CD25+FOXP3+ Tregs are scarce in the peripheral blood and HLA-matched donors are not always available, the efficacy and safety of Tregs from other sources have been evaluated for use in GVHD control (105). The gene discussed is FOXP3; the disease is graft versus host disease.